ES2127946T3 - Antagonistas de neurocinina diazabiciclica. - Google Patents

Antagonistas de neurocinina diazabiciclica.

Info

Publication number
ES2127946T3
ES2127946T3 ES94931148T ES94931148T ES2127946T3 ES 2127946 T3 ES2127946 T3 ES 2127946T3 ES 94931148 T ES94931148 T ES 94931148T ES 94931148 T ES94931148 T ES 94931148T ES 2127946 T3 ES2127946 T3 ES 2127946T3
Authority
ES
Spain
Prior art keywords
neurocinine
diazabyclic
antagonists
compounds
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94931148T
Other languages
English (en)
Inventor
Harry R Howard Jr
Kevin D Shenk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2127946T3 publication Critical patent/ES2127946T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DIAZABICICLICOS Y, ESPECIFICAMENTE A COMPUESTOS DE LA FORMULA (I), EN LA QUE A, G, R1, R2, R3, R4, R5, R6 Y R7 SON SEGUN SE DEFINEN EN LA ESPECIFICACION. LOS COMPUESTOS DE LA FORMULA (I) SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y DEL SISTEMA NERVIOSO CENTRAL, ASI COMO DE OTRAS ENFERMEDADES.
ES94931148T 1993-12-29 1994-11-14 Antagonistas de neurocinina diazabiciclica. Expired - Lifetime ES2127946T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17503493A 1993-12-29 1993-12-29

Publications (1)

Publication Number Publication Date
ES2127946T3 true ES2127946T3 (es) 1999-05-01

Family

ID=22638565

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94931148T Expired - Lifetime ES2127946T3 (es) 1993-12-29 1994-11-14 Antagonistas de neurocinina diazabiciclica.

Country Status (26)

Country Link
US (2) US5854239A (es)
EP (1) EP0737194B1 (es)
JP (1) JP2895630B2 (es)
KR (1) KR100197454B1 (es)
CN (1) CN1046515C (es)
AT (1) ATE177099T1 (es)
AU (1) AU699465B2 (es)
BR (1) BR9408450A (es)
CA (1) CA2180263C (es)
CO (1) CO4230019A1 (es)
CZ (1) CZ282567B6 (es)
DE (1) DE69416869T2 (es)
DK (1) DK0737194T3 (es)
ES (1) ES2127946T3 (es)
FI (1) FI108296B (es)
GR (1) GR3029853T3 (es)
HU (1) HUT74682A (es)
IL (1) IL112118A (es)
NO (1) NO305600B1 (es)
NZ (1) NZ274915A (es)
PE (1) PE49395A1 (es)
PL (1) PL179435B1 (es)
RU (1) RU2124014C1 (es)
TW (1) TW369526B (es)
WO (1) WO1995018129A1 (es)
ZA (1) ZA9410339B (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE177099T1 (de) * 1993-12-29 1999-03-15 Pfizer Diazabicyclische neurokinin antagonisten
FR2786770B1 (fr) * 1998-12-04 2001-01-19 Synthelabo Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique
DK1246806T3 (da) 1999-11-03 2008-06-16 Amr Technology Inc Aryl- og heteroarylsubstituerede tetrahydroisoquinoliner og anvendelse deraf til blokering af genoptagelse af norepinefrin, dopsmin og serotonin
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
WO2001095904A1 (en) * 2000-06-12 2001-12-20 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist
MXPA03000275A (es) 2000-07-11 2004-12-13 Albany Molecular Res Inc Nuevas tetrahidroisoquinolinas substituidas con 4-fenilo y su uso terapeutico.
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
SE0003795D0 (sv) * 2000-10-20 2000-10-20 Astrazeneca Ab Pharmaceutically useful compounds
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
PT1551835E (pt) * 2002-09-30 2007-03-30 Neurosearch As Novos derivados de 1, 4-diazabicicloalcano, sua preparação e utilização
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
RU2338746C2 (ru) * 2003-02-27 2008-11-20 НьюроСёрч А/С Новые диазабициклические арильные производные, содержащие их фармацевтические композиции и их применение
RU2368614C2 (ru) * 2004-02-04 2009-09-27 НьюроСёрч А/С Диазабициклические арильные производные в качестве модуляторов холинергических рецепторов
RU2386633C2 (ru) * 2004-05-07 2010-04-20 Мемори Фармасьютиклз Корпорейшн 1h-индазолы, бензотиазолы, 1, 2-бензоизоксазолы, 1, 2-бензоизотиазолы и хромоны и их получение и применения
UA91341C2 (ru) 2004-07-15 2010-07-26 Амр Текнолоджи, Інк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
US20060281670A1 (en) * 2005-06-10 2006-12-14 Wisconsin Alumni Research Foundation (Warf) Compositions and methods for modulating angiogenesis
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
TWI405763B (zh) * 2006-11-02 2013-08-21 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
JP5038509B2 (ja) 2008-01-18 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤
US8598184B2 (en) 2008-03-03 2013-12-03 Tiger Pharmatech Protein kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
ES2446971T3 (es) 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
CN102595902B (zh) 2009-05-12 2015-04-29 阿尔巴尼分子研究公司 7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
SI2657234T1 (sl) * 2010-12-22 2017-06-30 Meiji Seika Pharma Co., Ltd. Derivat optično-aktivnega diazabiciklooktana in metoda za njegovo izdelavo
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
BR112013028813B1 (pt) * 2011-08-27 2020-10-20 Wockhardt Limited derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e composições farmacêuticas que os compreendem
CN103649088B (zh) * 2011-08-30 2016-05-11 沃克哈特有限公司 1, 6- 二氮杂双环[3, 2, 1]辛- 7- 酮衍生物及其在治疗细菌感染中的用途
BR112014003476A2 (pt) * 2011-09-13 2017-03-01 Wockhardt Ltd compostos contendo nitrogênio e seu uso
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
HUE046893T2 (hu) * 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
SMT201700595T1 (it) 2012-11-28 2018-03-08 Merck Sharp & Dohme Composizioni e metodi per trattare il cancro
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
CN105164132A (zh) * 2013-03-08 2015-12-16 沃克哈特有限公司 (2s,5r)-6-苄氧基-7-氧代-1,6-二氮杂-双环[3.2.1]辛烷-2-羧酸钠及其制备方法
BR112015021186A2 (pt) * 2013-03-08 2017-07-18 Wockhardt Ltd processo para a preparação de (2s,5r)-7-oxo-6-sulfóxi-2-[((3r)-pirrolidina-3-carbonil)-hidrazino carbonil]-1,6-diaza-biciclo[3.2.1]octano
AU2013380574B2 (en) * 2013-03-08 2016-07-07 Wockhardt Limited A process for preparation of (2S, 5R)-7-oxo-6-sulphooxy-2-[((3R)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane
NZ711329A (en) * 2013-03-08 2016-06-24 Wockhardt Ltd A process for preparation of (2s, 5r)- sulfuric acid mono-{ [(4-aminopiperidin-4-yl) carbonyl]-7-oxo-1,6-diaza-bicyclo[3.2.1]-oct-6-yl} ester
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
DK3050883T3 (da) * 2013-09-24 2020-05-25 Meiji Seika Pharma Co Ltd Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
TWI690317B (zh) 2014-11-17 2020-04-11 英商安特西醫療有限公司 用於治療抗藥性細菌感染之組合療法
EP3277277B1 (en) * 2015-04-03 2021-01-06 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
SG11201901658PA (en) 2016-09-16 2019-04-29 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
PT3630111T (pt) 2017-05-08 2022-03-01 Entasis Therapeutics Inc Compostos e métodos de tratamento de infeções bacterianas
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CN108610313B (zh) * 2018-06-08 2022-03-04 三峡大学 一种酶抑制剂及其应用
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3494923A (en) * 1965-05-28 1970-02-10 Sterling Drug Inc 1,2,3,4,5,8-hexahydro-1,5-methanobenzo (f)(1,4)diazocine
SU482990A1 (ru) * 1973-09-03 1978-04-15 Предприятие П/Я Г-4059 Способ получени 1,4-диазабицикло(2,2,2)-октана
JPS5572177A (en) * 1978-11-27 1980-05-30 Shionogi & Co Ltd 4,1-benzoxazepine or 4,1-benzothiazepine
DE3122670A1 (de) * 1981-06-06 1982-12-23 Dr. Karl Thomae Gmbh, 7950 Biberach "neue 1,4,9,10-tetrahydro-pyrazolo(4,3-e) pyrido(3,2-b)(1,4)diazepin-10-one, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von pharmazeutischen wirkstoffen"
DE3124013A1 (de) * 1981-06-19 1982-12-30 Kali-Chemie Pharma Gmbh, 3000 Hannover 2-acylaminomethyl-1,4-benzodiazepin-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
HU184960B (en) * 1981-07-20 1984-11-28 Richter Gedeon Vegyeszet Process for preparing new derivatives of 3,7-diazabicyclo/3.3.1/ nonane
DE69200921T2 (de) * 1991-03-01 1995-05-04 Pfizer 1-azabicyclo[3.2.2]nonan-3-aminderivate.
ATE177099T1 (de) * 1993-12-29 1999-03-15 Pfizer Diazabicyclische neurokinin antagonisten

Also Published As

Publication number Publication date
DE69416869D1 (de) 1999-04-08
ATE177099T1 (de) 1999-03-15
US5854239A (en) 1998-12-29
IL112118A0 (en) 1995-03-15
CA2180263C (en) 2000-05-16
EP0737194B1 (en) 1999-03-03
CZ282567B6 (cs) 1997-08-13
DK0737194T3 (da) 1999-09-27
HU9601790D0 (en) 1996-09-30
RU2124014C1 (ru) 1998-12-27
ZA9410339B (en) 1996-06-28
FI946140A0 (fi) 1994-12-28
NO962742L (no) 1996-06-28
NO962742D0 (no) 1996-06-28
JP2895630B2 (ja) 1999-05-24
PL315193A1 (en) 1996-10-14
JPH09500904A (ja) 1997-01-28
GR3029853T3 (en) 1999-07-30
TW369526B (en) 1999-09-11
AU699465B2 (en) 1998-12-03
FI946140L (fi) 1995-06-30
FI108296B (fi) 2001-12-31
WO1995018129A1 (en) 1995-07-06
HUT74682A (en) 1997-01-28
KR100197454B1 (ko) 1999-06-15
EP0737194A1 (en) 1996-10-16
AU8002194A (en) 1995-07-17
CZ188696A3 (en) 1996-10-16
PL179435B1 (pl) 2000-09-29
CN1139434A (zh) 1997-01-01
BR9408450A (pt) 1997-08-05
PE49395A1 (es) 1996-01-06
CN1046515C (zh) 1999-11-17
US6110919A (en) 2000-08-29
IL112118A (en) 1998-10-30
NZ274915A (en) 1997-11-24
DE69416869T2 (de) 1999-07-01
CO4230019A1 (es) 1995-10-19
NO305600B1 (no) 1999-06-28

Similar Documents

Publication Publication Date Title
ES2164657T3 (es) Derivados aza-biciclicos puenteados como antagonistas de la sustancia p.
ES2147759T3 (es) Heterociclos no aromaticos sustituidos con aminometileno y uso como antagonistas de la sustancia p.
ES2092113T3 (es) Derivados fluoroalcoxibencilamino de heterociclos que contienen nitrogeno.
MX9301634A (es) Quinuclidinas peptidicas.
MX9304698A (es) Heterociclos que contienen nitrogeno substituido.
ES2164072T3 (es) Heterociclos no aromaticos que contienen nitrogeno sustituidos con bencilamino.
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
ES2111650T3 (es) Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p.
PA8521501A1 (es) Ligandos para receptores de melanocortina
ES2190430T3 (es) Nuevas sulfonamidas.
DK0737194T3 (da) Diazabicykliske neurokininantagonister
UY28150A1 (es) Agentes terapeuticos
ES2064667T3 (es) Derivados de 3-aminopiperidina y heterociclos relacionados que contienen nitrogeno.
ES2071334T3 (es) Analogos de anillos fusionados de nitrogeno conteniendo heterociclos no aromaticos.
ES2113368T3 (es) Antagonistas de serotonina.
GT200100160A (es) Derivados 4-fenil-piridina.
ES2194918T3 (es) Compuestos de tiazol y tiadiazol como ligando receptor de dopamina d3.
UY27026A1 (es) Derivados benzodiacepínicos como moduladores de los receptores gaba a
ES2062374T3 (es) Heteroarilpiperazinas, agentes antipsicoticos.
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
ES2038707T3 (es) Procedimiento para la obtencion de enantiomeros (+) y (-) de derivados de la 3,4-dihidro-2h-(1)-benzopiran-3-amina.
AR024747A1 (es) Derivados de aminotiazoles, su preparacion y las composiciones farmaceuticas que los contienen.
PA8458301A1 (es) 2-aminopiridinas con sustituyentes alcoxi ramificados
ES2110260T3 (es) Androstenonas.
ES2151168T3 (es) N-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 737194

Country of ref document: ES